TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02518152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Oral prophylaxis followed by Open flap debridement (OFD)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)+1% Alendronate
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
Study: NCT02247284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNFL and BMO-MRW SD-OCT
Description: Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
Study: NCT01126957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol given to both arms to maintain sedation throughout procedure.
Study: NCT05600413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: 4 weeks of L-Citrulline supplementation (6 grams/day)
Study: NCT01924052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CGRP
Description: Calcitonin-gene-related-peptide (CGRP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CGRP
Description: Calcitonin-gene-related-peptide (CGRP)
Study: NCT02935114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 37% Carbamide Peroxide
Description: * no Gingival dam protection (as manufacturer´s instruction)~* 37% Carbamide Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 35% hydrogen Peroxide
Description: * Gingival dam protection (as manufacturer´s instruction)~* 35% Hydrogen Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation
Study: NCT04753814

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagostic tests
Description: Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagostic tests
Description: Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagostic tests
Description: Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
Study: NCT00645294

Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir dipivoxil
Description: 0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8

Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir Dipivoxil
Description: 0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8

Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir Dipivoxil
Description: ADV 10 mg on Day 1
Study: NCT02822911

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alcohol Used Disorders Identification Test (AUDIT C)
Description: The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Carbohydrate deficient transferrin
Description: Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gamma glutamyl transpeptidase
Description: Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mean Corpuscular Volume
Description: Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
Study: NCT02836860

Intervention type: OTHER
Group type: OTHER
Intervention: Tactile stimuli
Description: Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5

Intervention type: OTHER
Group type: OTHER
Intervention: Tactile stimuli
Description: Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
Study: NCT05600413

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of Placebo (crystalline cellulose)
Study: NCT03789708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Instantly soluble granules of Gum Arabic; 100% Acacia Senegal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Instantly soluble granules of Gum Arabic; 100% Acacia Senegal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
Study: NCT03561064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Eligible participants will receive CBT-I by a licensed clinical psychologist.
Study: NCT02070666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective mechanical ventilation
Description: Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~* Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure \< 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~* Fraction of inspired oxygen inspired oxygen fraction (FiO2) \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cmH2O

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~* Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~  · FiO2 \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cm H2O.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dead space
Description: Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dead space
Description: Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
Study: NCT01698125

Intervention type: PROCEDURE
Intervention: Abdominal surgery
Description: Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
Study: NCT00534300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Intravenous infusion, 100 mL, 25mL/h
Study: NCT00851669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)
Description: Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individual psychotherapy following usual care practice in a chemical dependency treatment program.
Study: NCT01472146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zo-Nantax
Description: Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy
Study: NCT03674047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
Study: NCT01432613

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI-oriented muscle biopsy
Description: Orientation of muscle biopsy according to the MRI results
Study: NCT03324945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessments
Description: Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
Study: NCT04358939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone decubitus
Description: According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.
Study: NCT01665248

Intervention type: OTHER
Group type: OTHER
Intervention: 18-F Sodium Fluoride Uptake in Positron emission tomography
Study: NCT00535145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU), Paliperidone ER
Description: Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
Study: NCT03267966

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Leeds Pathology Protocol (LEEPP)
Description: LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
Study: NCT02878772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinpocetine
Description: 30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 100mg, once daily, oral medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg, once daily, oral medication
Study: NCT03260140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral lifestyle intervention
Description: The investigators will provide participants with the behavioral lifestyle intervention
Study: NCT03789708

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin powder, easily soluble
Study: NCT01909544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatiguing exercise
Description: All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fatiguing exercise
Description: All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
Study: NCT02526784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Study: NCT02882035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OFA
Study: NCT04056611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 250 mg
Description: JNJ-53718678 250 mg will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 250 mg
Description: JNJ-53718678 250 mg will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 125 mg
Description: JNJ-53718678 125 mg will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 125 mg
Description: JNJ-53718678 125 mg will be administered orally.
Study: NCT00003375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01042639

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: passive physical activity
Description: extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
Study: NCT01625130

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli sprout homogenate
Description: Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: alfalfa sprout homogenate
Description: 200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
Study: NCT01042639

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: passive physical activity
Description: extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: passive physical activity
Description: extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
Study: NCT04773717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: 200mg/kg/24h in four equal parts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same regimen as ascorbic acid.
Study: NCT03438227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron dextran
Description: Single intravenous infusion of iron dextran 1000mg.
Study: NCT03127280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Track foley removal
Description: Foley catheter is removed at 4 hours after surgery
Study: NCT03438227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Oral iron supplementation with ferrous sulfate 325mg one to three times daily
Study: NCT04712149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weekly digital follow up
Description: weekly digital follow-up by sending a questionnaire to patients and sending alerts based on the questionnaire to the care team
Study: NCT01570348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic BMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02526784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Study: NCT01215851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg tablet, once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg tablet, once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg tablet, once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Dosed by Weight
Study: NCT00229593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestorone gel
Description: 2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
Study: NCT01215851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Dosed by Weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour
Description: Rifafour e-275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: moxifloxacin 400 mg
Study: NCT04572334

Intervention type: OTHER
Group type: OTHER
Intervention: Auto and Subjective Refraction
Description: All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction

Intervention type: OTHER
Group type: OTHER
Intervention: Auto and Subjective Refraction
Description: All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
Study: NCT03172143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesenteric Sparing Ileocolic Resection
Description: In this resection, the mesentery will be spared, or left in situ during resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Ligation Ileocolic Resection
Description: In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen.
Study: NCT02681393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure and Telephone Support
Description: Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Participants will receive both the Aerobic Exercise After Stroke educational brochure.
Study: NCT01336946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho educational and behavioural group sessions
Description: 10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
Study: NCT03198156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation